FDA Approves First Smallpox-Indicated Treatment, SIGA's TPOXX

12:47 EDT 13 Jul 2018 | Genetic Engineering News

The FDA today approved the first drug indicated for smallpox, SIGA Technologies’ TPOXX® (tecovirimat), which was developed with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). TPOXX is a small molecule antiviral therapy designed to mitigate the impact of a potential outbreak of smallpox. While the disease was declared to have been eradicated by the World Health Organization in 1980, the U.S. and other nations have prioritized development of medical countermeasures against bioweapons in the years since September 11, 2001, when al-Qaeda terrorists mass-murdered 2,977 people on American soil. “To address the risk of bioterrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that could be employed as weapons. Today’s approval provides an important milestone in these efforts,” FDA Commissioner Scott Gottlieb, M.D., said in a statement issued by the agency. “This new ...

Original Article: FDA Approves First Smallpox-Indicated Treatment, SIGA's TPOXX


More From BioPortfolio on "FDA Approves First Smallpox-Indicated Treatment, SIGA's TPOXX"

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...